Crude aqueous extract from seeds (AEs) of Guettarda angelica Mart. (Rubiaceae) presented in vitro antiviral activity against bovine (BoHV-1) and swine (SuHV-1) herpesviruses type 1 in our previous studies. The aim of the current work was to continue the studies with this extract in order to determine its mode of antiviral action on these two animal herpesviruses. For this, at non cytotoxic concentration (40 µg/mL), the AEs extract was added at different times to the cells or viruses during infection. The antiviral tests were performed using the viral titer reduction assay and expressed in inhibition percentage (IP). The mechanism studies showed that AEs blocked BoHV-1 binding to MDBK cells in 99%; inhibited both during and after virus adsorption by more than 97% for both viruses. Moreover, AEs inactivated both viruses extracellular and directly by 99%. These results indicate that AEs has a broad spectrum of action since it was able either to exert a direct virucidal effect or to present an antiviral activity before and after the attachment phase. Seeds of G. angelica might be a promising source of antiviral agents and merits further investigation.
INTRODUCTION
Despite all the progress of modern medicine, researches on natural products, and specially on plants, have significantly progressed over the last decades. Besides, even with the great advancement of organic chemistry, these studies have confirmed the importance of these substances in the development of new biological and medicinal agents (Cowan 2009 , Calixto 2000 , Rates 2001 , Cos et al. 2006 ). Viral infections are still a serious worldwide problem and thus the plants would provide an alternative approach for the discovery of new antiviral agents.
Several papers have reviewed the progress and the perspectives of these plant antivirals (Cowan 2009 , Jassim & Naji 2003 , Martim & Ernest 2003 , Cos et al 2006 .
The family Herpesviridae comprises a number of important human and animal pathogens.
The virions are enveloped and contain an icosahedral nucleocapside and a double-stranded DNA genome (Murphy et al. 1999 , Gluckman 2009 ). Bovine herpesvirus type 1 (BoHV-1) is VIRUS REVIEWS AND RESEARCH 15, Nr. 2, 2010 80 responsible for various clinical manifestations in cattle including the disease called infectious bovine rhinotracheitis (IBR) and reproductive disorders. Swine herpesvirus type 1 (SuHV-1) is the causative agent of the Aujeszky's disease (AD); its viral replication including pathological changes in the respiratory and reproductive tracts and nervous system of pigs is responsible by disorders in these organs (Murphy et al. 1999) . These viruses establish a long life relationship with the host cells due to the characteristic of inducing latency. Since many viruses have unique features in their structure or in their replication cycle, these viral products can constitute potential targets for inhibitory agents (Jassim & Naji 2003) .
Many plants species have been investigated for their antiviral activity and some of them showed an inhibition on these two animal herpesviruses. Among others, Melia azedarach, Persea americana and Acanthospermum hispidum exhibited in vitro antiviral effect against SuHV-1 ( Descalzo & Coto 1989 , Simoni et al. 1996 , Summerfield et al. 1997 . Likewise, Phylantus orbicularis, Guazuma ulmifolia and Stryphnodendron adstringes inhibited in vitro the BoHV-1 (Barrio & Parra 2000, Felipe et al. 2006) . Furthermore, several plant species belonging to the diverse families in an antiviral screening of Brazilian cerrado and Pantanal wetland plants presented an inhibitory effect for both viruses (Hoe 2003 , Biltovani 2006 ).
The antiviral studies with these animal herpesviruses can serve as an in vitro experimental model for other herpesviruses and/or DNA viruses. Another application could be the prophylactic use in bovine semen ensuring a safety genetic material when the practice of artificial insemination.
Guettarda angelica Mart. (Rubiaceae), known as "Angélica do mato", is member of the Rubiaceae family being found in Caatinga region of the northeast of Brazil (SEPLANTEC 1979 , Flora Brasiliensis 2008 ). In our previous antiviral studies, the seeds of G. angelica presented promising antiviral results against these animal herpesviruses (Barros et al. 2007 ). It has been described in the literature the antiviral activity of extracts from seeds against diverse human and animal viruses (Tailor et al. 1997 , Shahat et al. 2001 , Gonçalves et al. 2005 . Thus, the aim of the VIRUS REVIEWS AND RESEARCH 15, Nr. 2, 2010 81 present work was continue the searches with the crude aqueous extract from seeds (AEs) of G.
angelica investigating its possible mechanism of action against BoHV-1 and SuHV-1.
MATERIAL AND METHODS

Plant extract.
Guettarda angelica Mart. (Rubiaceae) was collected in the region of Jequié, Bahia State, Brazil. The voucher specimen (No. 315) was deposited in the herbarium of the Centro de Pesquisa do Cacau, at same State. The preparation of the crude aqueous extract from seeds (AEs) of G. angelica was described in our previous study (Barros et al. 2007 ). Briefly, the ground dried seeds were dissolved in distilled water (10%, w/v) during 8 h at 4 o C under agitation, filtered and freeze-dried. Then, the extract AEs was re-dissolved in equal parts of distilled water and Earle minimum essential medium (MEM-Vitrocell) at final concentration of 4 mg/mL. The maximum non cytotoxic concentration (MNCC) of AEs on cells MDBK (40 µg/mL) used in the antiviral assays was also previously obtained.
Cells and viruses.
Madin Darby bovine kidney cells (MDBK) (ATCC-CCL 22) were grown in MEM supplemented with 10% fetal calf serum (FCS). Bovine herpesvirus type 1 (BoHV-1), strain Los Angeles ) with titer of 10 7.16 TCID 50 /mL, and swine herpesvirus type 1 (SuHV-1), strain Nova Prata (Fonseca et al. 2010 ) with titer of 10 6.41 TCID 50 /mL. Both strains are acyclovir-resistant (data not published).
Mode of antiviral activity assay.
In order to determine the mode of antiviral action of AEs on BoHV-1 and SuHV-1, this extract was added at different times to the cells or viruses during infection according to the method described by Schuhmacher et al. (2003) with modifications.
For the assays, MDBK cells were prepared in 96-well microplates at density of 3 x 10 4 cells per well and incubated for 24h at 37ºC with 5% CO 2 . After this time period, the cells were submitted to different treatments which are described below and returned to incubation for at
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(PreT) pretreatment.
Cells were exposed to the extract prior the viral infection. The growth medium was exchanged by 100 µL of AEs at MNCC and after 1 h, the extract was removed by washing with phosphate-buffered saline (PBS). Then, it was added 100 µL of MEM without FCS (maintenance medium) and the cells were infected with 50 µL of viral logarithmic dilutions.
(AD) adsorption.
The extract was added at the moment of cell infection. The growth medium was removed to the microplate and 100 µL of the extract at MNCC were added along with 50µL of viral logarithmic dilutions. After the adsorption period (1 h), the cells were washed and supplemented with 100 µL of maintenance medium.
(PosT) post treatment.
The cells were exposed to the extract during the post-infection phase only. Firstly, there was the interchange of growth medium by one of the maintenance (100 µL) and then the cells were infected with 50 µL of viral logarithmic dilutions. After the adsorption period and washing procedure, the extract at MNCC was added (100 µL).
Virucidal assay.
The virucidal effect was assessed using the technique described in Simoni et al. (1996) .
Equal parts of extract at MNCC and virus (log 10 dilutions) were mixed and incubated at 37ºC for 1 h. Controls consisted of viral dilutions with medium only. Then, these mixtures (100 µL) were inoculated into microplates containing 24 h growing cells and without growth medium.
(VC) viral control.
To calculate the viral titer in each treatment, the cells were infected with virus without extract. The growth medium was interchanged by 100 µL of one without FCS followed by addition of 50 µL of logarithmic viral dilutions.
(AV) antiviral control.
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To confirm the antiviral activity of AEs, the antiviral assay described in Simoni et al. (2007) was included in all the treatments. After the interchange of growth medium by 100 µL of the extract and incubation for 1 h, 50 µL of logarithmic viral dilutions were added. In addition, to verify if the antiviral activity of the extract remained below its MNCC, a dose-response experiment was carried out using it at 10 and 20 µg/mL.
Data analysis.
The antiviral activities were based in reduction of viral titers using CPE criteria and expressed as viral inhibition index (VII) and/or inhibition percentage (IP). The VII was calculated as the difference of virus titer between treated and untreated control cultures using logarithmic TCID50 values ). The IP was calculated using the anti-logarithmic TCID50
values (Nishimura et al. 1977) . The data were statistically compared using the one way analysis of variance (ANOVA) with a Tukey-Kramer multiple comparisons test. The significance level was *<0.05 and ** <0.01.
RESULTS
The antiviral activity of AEs against BoHV-1 and SuHV-1 was evaluated on the replication period by adding the extract before, during and after the adsorption phase. The results obtained by these treatments are described in AT: extract added only at the moment of cell infection; PosT: extract added after cell infection.
The direct and extracellular effect of AEs on these viruses was also investigated. Thus, the residual infectivity of mixtures of virus dilutions plus extract was evaluated. The results are also shown in Table 1 and demonstrated a virucidal effect of AEs against BoHV-1 (VII= 2.67, p<0.01) and SuHV-1 (VII=3.5, p<0.01) by 99%.
An additional study was performed to evaluate an antiviral dose-dependent effect of AEs (Figure 1) . Thus, the cells were exposed at concentrations bellow the maximum non-cytotoxic concentration (MNCC) in antiviral assay (AV). As well as at MNCC (40 µg/mL), the extract presented an antiviral activity one dilution bellow (20 µg/mL) for both viruses. However, the inhibition was less effective showing lower viral inhibition index (VII). The VII was 1.5 (p<0.05) and 2.03 (p<0.05) for BoHV-1and SuHV-1, respectively. From 10 µg/mL, there was the loss of
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Figure 1. Dose-response experiments of the seed aqueous extract of Guettarda angelica against bovine (-♦-) and swine (---■---) herpesviruses in cells MDBK
DISCUSSION
Plants material used in antiviral experiments comes from different sources as leaves, seeds or roots. These diverse parts contain a wide variety of chemicals constituents which might exert an inhibition on the viruses. Nowadays, the choice of plant and/or of its material is more focused from their traditional or medicinal use (Cowan 1999 , Rates 2001 , Jassim & Naji 2003 , Cos et al. 2006 . Root barks of Guettarda angelica are used in veterinary medicine against bovine and equine diarrhea (SEPLANTEC 1979) . Studies developed by one part of our group using methanolic and aqueous extracts from bark roots of this plant demonstrated in vitro an antibacterial activity against gram positive bacteria (Bispo et al. 2007 ). On the other hand, our subsequent antiviral studies with BoHV-1 and SuHV-1 showed that the roots of G. angelica did not presente antiviral activity while its seeds presented (Barros et al. 2007) . Crude products can be used in a variety of assays to screen for antiviral activity. In this paper, we focused on the mode of action of the crude extract from seeds (AEs) of G. angelica on these viruses proceeding with more detailed evaluations.
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86 These approaches permitted to evaluate the direct effect on the viruses in extracellular conditions or the effect in different steps of replication period. Different treatments could be followed: pretreatment which consists of verifying if the extracts can incite an "antiviral state" similar to interferon action; attachment which permits to study the effect of the extract in the adsorption/penetration phase; and post treatment that is used to verify the effect of the presumed antiviral compound in the replication phase (Cowan 1999) . Results from these treatments indicated that the AEs had a broad antiviral spectrum in vitro. The antiviral activity of this extract probably derived from its direct inactivation of the virus and/or from inhibition in one or more phases on replication cycle. Other reports verified that certain plants or compound suppressed human herpesviruses infections (HSV-1 and HSV-2) through many modes of action (Schuhmacher et al. 2003 , Cheng et al. 2005 . Our results also demonstrated a dose-dependent antiviral response of the AEs extract with an activity at concentrations bellow its MNCC. Anyway, assays to determine the therapeutic index (IS) of this extract from its 50% cytotoxic concentration (CC 50 ) and 50% inhibitory concentration (IC 50 ) against these viruses are ongoing.
Studies with semen infected experimentally with BoHV-1 and treated with trypsin at different concentrations suggested that trypsin treatments were effective against the virus however the effects on semen quality and the possibility of a decrease in semen fertility were clear (Silva et al. 1999) . A pokeweed antiviral protein (PAP) purified from the leaves of
87 Phytolacca americana showed to act both as a non spermicidal intravaginal microbicidal and as a prophylactic antiviral agent against HIV-1. This protein, among other characteristics, did not affect the sperm motility and the cytotoxicity (D'Cruz & Uckun 2001).In the same way, the use of a natural product that inhibits the virus without to cause these effects would be a worth alternative for bovine in vitro fertility (IVF) technology.
